Clinical trial NCT02289456: Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
Official title: A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Phase II, LOCALLY ADVANCED OR METASTATIC NON SMALL
CELL LUNG CANCER (NSCLC) AND AN
EASTERN COOPERATIVE ONCOLOGY GROUP
PERFORMANCE STATUS OF 2
(ABOUND.PS2)
LOCALLY ADVANCED OR METASTATIC NON SMALL
CELL LUNG CANCER (NSCLC) SUBJECTS THAT AE NOT CANDIDATES FOR RADIATION OR CURATIVE SURGERY
Lead sponsor: Celgene
Sponsor class: INDUSTRY
First posted: 2014-11-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.


Eligibility criteria: Inclusion Criteria:

* General and Demographics

  1. Age ≥ 18 years of age at the time of signing the Informed Consent Form.
  2. Understand and voluntarily provide written consent to the Informed Consent Form prior to conducting any study related assessments/procedures.
  3. Able to adhere to the study visit schedule and other protocol requirements. Disease Specific
  4. Histologically or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung Cancer.
  5. Radiographically documented measurable disease at study entry per response evaluation criteria in solid tumours ( RECIST) v1.1.
  6. No prior anti-cancer therapy for the treatment of metastatic disease at the time of signing the ICF. Adjuvant treatment is permitted providing cytotoxic chemotherapy was completed 12 months prior to signing the ICF and without disease recurrence.
  7. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.
  8. Platelets ≥ 100,000 cells/mm3.
  9. Hemoglobin (Hgb) ≥ 9 g/dL.
  10. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase \[SGOT\]), alanine transaminase (ALT/serum glutamic pyruvic transaminase \[SGPT\]) ≤ 2.5 × upper limit of normal range (ULN) or ≤ 5.0 × ULN if liver metastases.
  11. Total bilirubin ≤ 1.5 × ULN except in cases of Gilbert's disease and liver metastases.
  12. Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 40 mL/min (if renal impairment is suspected 24-hour urine collection for measurement is required).
  13. Eastern Cooperative Oncology Group Performance Status 2.
  14. Females of childbearing potential \[defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months)\] must:

      1. Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(ß-hCG) as verified by the study doctor within 72 hours prior to starting study therapy.
      2. You must commit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved contraception throughout the study without interruption; while receiving study medication or for a longer period if required by local regulations.

         Male subjects must:
      3. practice true abstinence\* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.

Exclusion Criteria:

* The presence of any of the following will exclude a subject from enrollment:

  1. Evidence of active brain metastases, including leptomeningeal involvement (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for at least 21days prior to signing ICF). MRI of the brain (or CT scan w/contrast) is preferred for diagnosis.
  2. History of leptomeningeal disease.
  3. Only evidence of disease is non-measurable.
  4. Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse Events (CTCAE) v4.0).
  5. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting investigational product (IP), and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
  6. Venous thromboembolism within 1 month prior to signing ICF.
  7. Current congestive heart failure (New York Heart Association Class II-IV).
  8. History of the following within 6 months prior to first administration of investigational product: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant ECG abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.
  9. Subject has a known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.
  10. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
  11. History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.
  12. Treatment with any investigational product within 28 days prior to signing the ICF.
  13. History of or suspected allergy to nab-paclitaxel, carboplatin and human albumin or any other platinum-based therapy.
  14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.
  15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.
  16. Subject has any other malignancy within 5 years prior to signing the ICF. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (Tumor, node and metastasis (TNM) stage of T1a or T1b). All treatment should have been completed 6 months prior to signing ICF.
  17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  18. Any medical condition that confounds the ability to interpret data from the study. This includes subjects with known psychiatric disorders.
  19. Pregnant or breast-feeding females.
  20. Subjects with an ECOG PS other than 2

Primary outcomes:
measure: Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).
timeFrame: From date of the first dose of IP until 28 days after the last dose of IP during induction and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; maximum treatment duration during induction was 3.9 months
Secondary outcomes:
measure: Percentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)
timeFrame: From date of the first dose of IP until 28 days after the last dose of IP during induction and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; maximum treatment duration during induction was 3.9 months
measure: Dose Intensity of Nab-Paclitaxel During the Entire Study
timeFrame: From Day 1 of study treatment to end of study treatment; maximum treatment duration on study was 14.1 months
measure: Dose Intensity of Carboplatin During the Entire Study
timeFrame: From Day 1 of study treatment to end of study treatment; maximum treatment duration on study was 14.1 months
measure: Percentage of Participants With Dose Reductions During the Entire Study
timeFrame: From day 1 of IP until 28 days after the last dose of IP; maximum treatment duration was 14.1 months during the entire study
measure: Kaplan Meier Estimate of Progression-Free Survival (PFS)
timeFrame: From Day 1 of study drug treatment to the date of disease progression; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
measure: Percentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)
timeFrame: Response assessments were evaluated every 6 weeks; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
measure: Kaplan Meier Estimate of Overall Survival (OS)
timeFrame: From Day 1 of study treatment to death from any cause; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
measure: Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines
timeFrame: Response assessments were evaluated every 2 cycles; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
measure: Time to Response
timeFrame: From Day 1 of study drug treatment to the date of first occurrence of CR or PR; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
measure: Kaplan Meier Estimate of Duration of Response
timeFrame: From Day 1 of study drug treatment to the date of first occurrence of CR or PR; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
measure: Number of Participants With TEAEs During the Induction and Monotherapy Periods
timeFrame: From date of the first dose of IP until 28 days after the last IP dose and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; up to cutoff date of 24 Feb 2017; maximum treatment duration was 14.1 months
Other outcomes:
measure: Percentage of Protocol Dose
timeFrame: From Day 1 of study drug treatment to end of study drug treatment; up to clinical data cut-off date of 24 February 2017; ; maximum treatment duration was 14.1 months.
Locations:
city: Boynton Beach
country: United States
facility: University Cancer Institute
state: Florida
city: New Orleans
country: United States
facility: Ochsner Clinic Nephrology
state: Louisiana
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Rochester
country: United States
facility: University of RochesterJames P. Wilmont Cancer Center
state: New York
city: Syracuse
country: United States
facility: SUNY Upstate Medical University
state: New York
city: Cincinnati
country: United States
facility: University of Cincinnati Medical Center
state: Ohio
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
Study officials:
affiliation: Celgene Corporation
name: Francois Lafleur, MD
role: STUDY_DIRECTOR
References: